Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.

Gemcitabine, an effective agent in treatment of cancer of pancreas, has undergone failures in many instances after multiple cycles of therapy due to emergence of drug resistance. Combination of dietary compounds with clinically validated drugs has emerged as an effective therapeutic approach to trea...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Archana Pandita, Bhupender Kumar, Siddharth Manvati, Samantha Vaishnavi, Shashank K Singh, Rameshwar N K Bamezai
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Online Access:	http://europepmc.org/articles/PMC4157832?pdf=render

Similar Items

Synergistic activity of troxacitabine (Troxatyl™) and gemcitabine in pancreatic cancer
by: Leblond Lorraine, et al.
Published: (2007-07-01)

Mapping of PARK2 and PACRG overlapping regulatory region reveals LD structure and functional variants in association with leprosy in unrelated indian population groups.
by: Rupali Chopra, et al.
Published: (2013-01-01)

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
by: Immacolata Maietta, et al.
Published: (2022-07-01)

Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
by: Renata Szydlak
Published: (2024-09-01)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
by: Junjie Li, et al.
Published: (2018-01-01)

FV-429 induces apoptosis by regulating nuclear translocation of PKM2 in pancreatic cancer cells
by: Xifan Jin, et al.
Published: (2024-04-01)

A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells
by: Ahmed Abdullah Ahmed, et al.
Published: (2020-11-01)

Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis
by: Jiaqiang Ren, et al.
Published: (2025-04-01)

Down regulation of miR-33a is involved in gemcitabine chemoresistance in human pancreatic cancer
by: 梁晨, et al.
Published: (2015-05-01)

Development of Novel Small-Molecule Activators of Pyruvate Kinase Muscle Isozyme 2, PKM2, to Reduce Photoreceptor Apoptosis
by: Thomas J. Wubben, et al.
Published: (2023-05-01)

In silico screening, genotyping, molecular dynamics simulation and activity studies of SNPs in pyruvate kinase M2.
by: Ponnusamy Kalaiarasan, et al.
Published: (2015-01-01)

Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells.
by: Sumit Arora, et al.
Published: (2011-01-01)

Synergistic effects of resveratrol with gemcitabine in pancreatic cancer chemotherapy by inhibiting the c-Met/PARP1 axis
by: Shuai Wu, et al.
Published: (2024-12-01)

Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
by: Yongwei Wang, et al.
Published: (2012-01-01)

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
by: Zhang-qi Cao, et al.
Published: (2020-11-01)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01)

Gemcitabine-induced β4 integrin drives cancer progression and gemcitabine resistance in pancreatic cancer
by: Yoshinobu Kariya, et al.
Published: (2026-04-01)

Simultaneous suppression of PKM2 and PHGDH elicits synergistic anti-cancer effect in NSCLC
by: Kaixuan Wang, et al.
Published: (2023-05-01)

PKM2 Expression and Elevated CD163 in Macrophage Synergistically Promote Osteosarcoma Progression
by: TAN Wenfu, et al.
Published: (2019-12-01)

Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
by: Phonpilas Thongpon, et al.
Published: (2024-07-01)

WWOX rs11644322 polymorphism, gemcitabine, and pancreatic cancer
by: Sora Yasri, et al.
Published: (2017-01-01)

An unusual pAIR: Anti-PKM2 antibody and occult pancreatic adenocarcinoma
by: Meredith P. Spitz, et al.
Published: (2024-12-01)

Coumarin: An emerging antiviral agent
by: Shruti Mishra, et al.
Published: (2020-01-01)

SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells
by: Minsoo Kim, et al.
Published: (2025-03-01)

Hexokinase 2 dimerization and interaction with voltage‐dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer
by: Kun Fan, et al.
Published: (2019-10-01)

Cardamonin Promotes the Apoptosis and Chemotherapy Sensitivity to Gemcitabine of Pancreatic Cancer Through Modulating the FOXO3a-FOXM1 Axis
by: Huapeng Sun, et al.
Published: (2021-12-01)

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
by: Kentaro Minami, et al.
Published: (2015-03-01)

Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy
by: Erez Hasnis, et al.
Published: (2014-06-01)

Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer
by: Geng Xu, et al.
Published: (2025-07-01)

Epibrassinolide Promotes the Apoptotic Potential of Gemcitabine in Pancreatic Cancer Cells
by: Fadina Kuryayeva, et al.
Published: (2019-12-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
by: Tianpeng Zhang, et al.
Published: (2023-12-01)

Senolysis of gemcitabine‐induced senescent human pancreatic cancer cells
by: Mohammad Mahbubul Hoque, et al.
Published: (2024-04-01)

Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
by: Inês Mendes, et al.
Published: (2024-01-01)

Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
by: Nicolas Alejandro Fraunhoffer, et al.
Published: (2022-11-01)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
by: Kaidong Liu, et al.
Published: (2022-08-01)

Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer
by: A. Rajabpour, et al.
Published: (2017-10-01)

The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues
by: Lin Li, et al.
Published: (2024-04-01)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
by: Haorui Li, et al.
Published: (2023-10-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
by: Zhou Zhu, et al.
Published: (2023-10-01)

The role of mitochondrial dysfunction in the cytotoxic synergistic effect of gemcitabine and arsenic on breast cancer.
by: Farshid Maleki, et al.
Published: (2025-01-01)